Bayer has announced it is investing €500m in Germany to create new manufacturing capacity for two hemophilia A treatments in its late-stage pipeline. The recombinant Factor VIII products in question are BAY 81-8973 and BAY 94-9027, both of which offer improvements over existing therapies.
The German group booked €1.2bn in sales in 2013 from its marketed hemophilia A therapy Kogenate FS, which is manufactured...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
